✦ LIBER ✦

Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

✍ Scribed by Raffi, François; Babiker, Abdel G; Richert, Laura; Molina, Jean-Michel; George, Elizabeth C; Antinori, Andrea; Arribas, Jose R; Grarup, Jesper; Hudson, Fleur; Schwimmer, Christine; Saillard, Juliette; Wallet, Cédrick; Jansson, Per O; Allavena, Clotilde; Van Leeuwen, Remko; Delfraissy, Jean-François; Vella, Stefano; Chêne, Geneviève; Pozniak, Anton

Book ID: 126830019
Publisher: The Lancet
Year: 2014
Tongue: English
Weight: 395 KB
Volume: 384
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(14)61170-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Once-daily dolutegravir versus twice-dai

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

✍ Raffi, François; Jaeger, Hans; Quiros-Roldan, Eugenia; Albrecht, Helmut; Belonos 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 274 KB

Once-daily dolutegravir versus raltegrav

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

✍ Raffi, Francois; Rachlis, Anita; Stellbrink, Hans-Jürgen; Hardy, W David; Torti, 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 368 KB

Simplification to coformulated elvitegra

Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial

✍ Arribas, Jose R; Pialoux, Gilles; Gathe, Joseph; Di Perri, Giovanni; Reynes, Jac 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 260 KB

Dual therapy with lopinavir and ritonavi

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial

✍ Cahn, Pedro; Andrade-Villanueva, Jaime; Arribas, José R; Gatell, José M; Lama, J 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 321 KB